Receive our newsletter – data, insights and analysis delivered to you
  1. Deals Analysis
March 15, 2019updated 03 Jan 2022 10:33am

Pharma deal activity for Q4 2018 reaches $21.11bn

Total pharma deals worth $21.11bn were announced during Q4 2018, according to GlobalData’s deals database.

 
 
  • Embed this chart 

    Embed this chart into your website

    Copy and paste the code below into your website to display the chart.

The value marked a decrease of 6.32% over the previous quarter and a drop of 64.84% when compared with the last four-quarter average of $60.07bn.

In terms of number of deals, the sector saw a drop of 7.18% over the last four-quarter average with 388 deals against the average of 418 deals.

In value terms, North America led the activity with deals worth $16.64bn.

The top announced deal, as tracked by GlobalData, in Q4 2018 was GlaxoSmithKline’s $5.1bn acquisition of TESARO.

Content from our partners
How Hengst helped to keep Germany’s charity “star singers” shining
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

The article considers only announced and completed deals from the GlobalData Financial Deals database and excludes all terminated and rumoured deals. GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU